Compare MCRB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCRB | NYXH |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 190.6M |
| IPO Year | 2015 | 2021 |
| Metric | MCRB | NYXH |
|---|---|---|
| Price | $9.03 | $4.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.33 | $11.67 |
| AVG Volume (30 Days) | ★ 100.7K | 52.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $126,325,000.00 | N/A |
| Revenue This Year | N/A | $97.32 |
| Revenue Next Year | N/A | $241.74 |
| P/E Ratio | $3.63 | ★ N/A |
| Revenue Growth | ★ 1672.24 | N/A |
| 52 Week Low | $0.36 | $3.92 |
| 52 Week High | $29.98 | $11.87 |
| Indicator | MCRB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 37.16 |
| Support Level | $7.12 | N/A |
| Resistance Level | $16.14 | $4.99 |
| Average True Range (ATR) | 0.96 | 0.31 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 16.03 | 8.37 |
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.